{"id":"ramipril-hoe498","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"3-8","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. Ramipril is used to manage hypertension and heart failure.","oneSentence":"Ramipril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:57.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy prevention"}]},"trialDetails":[{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT03475186","phase":"PHASE2","title":"Testing Ramipril to Prevent Memory Loss in People With Glioblastoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-03-25","conditions":"Glioblastoma, Radiotherapy; Complications, Cognitive Decline","enrollment":75},{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":"Hypertension, Fall Risk, Postural Balance","enrollment":186},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":"Pentoxifylline, Inflammatory Markers, Non-Diabetic","enrollment":42},{"nctId":"NCT01037530","phase":"PHASE4","title":"Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-12","conditions":"Intermittent Claudicants","enrollment":33},{"nctId":"NCT07259512","phase":"PHASE4","title":"Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","status":"RECRUITING","sponsor":"Evi Liliek Wulandari","startDate":"2025-06-30","conditions":"Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":80},{"nctId":"NCT05963568","phase":"PHASE3","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2026-01-01","conditions":"Stroke, Medication Adherence","enrollment":680},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT04983823","phase":"NA","title":"Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)","status":"RECRUITING","sponsor":"Baker Heart and Diabetes Institute","startDate":"2021-11-18","conditions":"Heart Failure","enrollment":820},{"nctId":"NCT07184918","phase":"NA","title":"Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-02-01","conditions":"Contrast-Induced Nephropathy, Coronary Angiography, Acute Kidney Injury","enrollment":44},{"nctId":"NCT05030818","phase":"PHASE4","title":"Cross-over Study of Coronary Risk Factors With a Polypill","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2022-10-14","conditions":"Coronary Artery Disease","enrollment":88},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":"Myocardial Infarct","enrollment":120},{"nctId":"NCT05942053","phase":"PHASE4","title":"Role of Vitamin K2 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":"Chronic Kidney Diseases","enrollment":44},{"nctId":"NCT07023016","phase":"PHASE2, PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":"Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)","enrollment":515},{"nctId":"NCT05942027","phase":"PHASE4","title":"Role of Coenzyme Q10 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":"Chronic Kidney Diseases","enrollment":44},{"nctId":"NCT07027774","phase":"PHASE4","title":"Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wannan Medical College","startDate":"2025-07-10","conditions":"Chronic Kidney Disease Stage 4","enrollment":429},{"nctId":"NCT03440177","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Ramipril","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT04962711","phase":"NA","title":"Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)","status":"RECRUITING","sponsor":"Baker Heart and Diabetes Institute","startDate":"2023-03-30","conditions":"Heart Failure","enrollment":685},{"nctId":"NCT02842424","phase":"PHASE4","title":"Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2016-02-25","conditions":"Peripheral Arterial Disease","enrollment":70},{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":"Myocardial Infarction, Cardiovascular Disease","enrollment":2499},{"nctId":"NCT06104423","phase":"PHASE4","title":"Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2023-10-02","conditions":"Hypertension","enrollment":266},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT04173949","phase":"PHASE3","title":"Explorative Study for Treating Persistent Developmental Stuttering With Ramipril","status":"ACTIVE_NOT_RECRUITING","sponsor":"HaEmek Medical Center, Israel","startDate":"2020-03-15","conditions":"Persistent Developmental Stuttering","enrollment":10},{"nctId":"NCT02901977","phase":"PHASE4","title":"Doxazosin and Ramipril in Hypertension","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2011-03","conditions":"Hypertension","enrollment":71},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT00829530","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT00829452","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT00828321","phase":"PHASE1","title":"Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02008786","phase":"PHASE4","title":"Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD","status":"TERMINATED","sponsor":"Cardiology Research UBC","startDate":"2014-06","conditions":"Coronary Artery Dissection, Spontaneous","enrollment":18},{"nctId":"NCT06304896","phase":"PHASE1","title":"Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Arab Contractors Medical Centre","startDate":"2024-05-01","conditions":"Chemotherapy Induced Systolic Dysfunction","enrollment":150},{"nctId":"NCT05685277","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-12-28","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Diabetic Kidney Disease","enrollment":70},{"nctId":"NCT00274599","phase":"PHASE4","title":"PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10-09","conditions":"Hypertension","enrollment":812},{"nctId":"NCT04366050","phase":"PHASE2","title":"Ramipril for the Treatment of COVID-19","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-05-11","conditions":"COVID-19","enrollment":160},{"nctId":"NCT01669434","phase":"PHASE4","title":"Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-06-01","conditions":"Hypotension on Induction","enrollment":291},{"nctId":"NCT04354350","phase":"","title":"Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Hypertension","enrollment":63744},{"nctId":"NCT05438316","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-06-17","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":"Acute Myocardial Infarction","enrollment":5669},{"nctId":"NCT05271448","phase":"NA","title":"Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-06-01","conditions":"Contrast-induced Nephropathy, Chronic Kidney Diseases, Ischemic Heart Disease","enrollment":600},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT03715998","phase":"PHASE2","title":"Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction","status":"COMPLETED","sponsor":"Quantum Genomics SA","startDate":"2019-06-04","conditions":"Myocardial Infarction","enrollment":295},{"nctId":"NCT04962841","phase":"","title":"Nutraceuticals and Drug Treatment in Frail Older Adults","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2020-04-01","conditions":"Frailty","enrollment":485},{"nctId":"NCT03099213","phase":"PHASE4","title":"An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-11-01","conditions":"Coronary Artery Disease","enrollment":179},{"nctId":"NCT03414723","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-15","conditions":"Diabetes Mellitus, Healthy Subjects","enrollment":16},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT02721342","phase":"","title":"Remission Clinic in Proteinuric Chronic Nephropathies","status":"UNKNOWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-06","conditions":"Chronic Kidney Disease","enrollment":1500},{"nctId":"NCT02236806","phase":"PHASE3","title":"Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2015-07","conditions":"Breast Cancer, Cardiotoxicity","enrollment":262},{"nctId":"NCT05133050","phase":"NA","title":"Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-01-01","conditions":"Alport Syndrome","enrollment":510},{"nctId":"NCT02499822","phase":"PHASE4","title":"REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2015-10","conditions":"Hypertension, High Blood Pressure Variability","enrollment":168},{"nctId":"NCT03201185","phase":"PHASE4","title":"Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2018-02-10","conditions":"Transcatheter Aortic Valve Replacemen, Angiotensin-Converting Enzyme Inhibitors","enrollment":194},{"nctId":"NCT01646437","phase":"PHASE3","title":"The International Polycap Study 3 (TIPS-3)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-06","conditions":"Cardiovascular Disease, Fractures, Cancers","enrollment":7793},{"nctId":"NCT04320589","phase":"PHASE2","title":"the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-06-30","conditions":"Pheochromocytoma","enrollment":30},{"nctId":"NCT03991910","phase":"PHASE3","title":"The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2019-06-27","conditions":"Rheumatic Heart Disease, Mitral Stenosis, Rheumatic Mitral Stenosis","enrollment":66},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":"Hypertension","enrollment":1111},{"nctId":"NCT02086019","phase":"NA","title":"Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes","status":"COMPLETED","sponsor":"Brighton and Sussex University Hospitals NHS Trust","startDate":"2014-05-01","conditions":"Acute Coronary Syndromes","enrollment":250},{"nctId":"NCT00985322","phase":"PHASE3","title":"Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-05","conditions":"Left Ventricular Hypertrophy, Hypertension","enrollment":269},{"nctId":"NCT04582097","phase":"PHASE2, PHASE3","title":"Ramipril in Pediatric Patients on Hemodialysis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-12-01","conditions":"Hemodialysis","enrollment":135},{"nctId":"NCT00980785","phase":"PHASE4","title":"Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-04-09","conditions":"Alzheimer's Disease, Hypertension","enrollment":14},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT02632747","phase":"PHASE2","title":"Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-05-10","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity","enrollment":31},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01485978","phase":"PHASE3","title":"Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2012-03","conditions":"Renal Insufficiency, Chronic","enrollment":66},{"nctId":"NCT04364139","phase":"PHASE3","title":"African American Study of Kidney Disease and Hypertension","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1995-02-01","conditions":"Hypertensive Nephrosclerosis, Chronic Renal Insufficiency","enrollment":1094},{"nctId":"NCT01686230","phase":"NA","title":"Acupuncture in Patients With Stable Angina Pectoris","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-07","conditions":"Angina, Stable","enrollment":404},{"nctId":"NCT02029118","phase":"EARLY_PHASE1","title":"Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-10","conditions":"Stable Angina Pectoris","enrollment":200},{"nctId":"NCT04262765","phase":"PHASE1","title":"Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin","status":"COMPLETED","sponsor":"Midas Pharma GmbH","startDate":"2019-02-23","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT04143412","phase":"PHASE2","title":"Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2019-02-04","conditions":"Diabetic Nephropathy Type 2, Microalbuminuria Due to Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT00512759","phase":"PHASE4","title":"Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-12-10","conditions":"Acute Heart Failure","enrollment":781},{"nctId":"NCT00574834","phase":"EARLY_PHASE1","title":"Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":17},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT03979976","phase":"PHASE2, PHASE3","title":"Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2011-03","conditions":"Systemic Lupus Erythematosus","enrollment":37},{"nctId":"NCT02832973","phase":"PHASE4","title":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","status":"COMPLETED","sponsor":"Sao Jose do Rio Preto Medical School","startDate":"2015-09","conditions":"Hypertension Resistant to Conventional Therapy","enrollment":72},{"nctId":"NCT03770936","phase":"PHASE3","title":"Effect of Some Drugs on Liver Fibrosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-10-01","conditions":"Liver Fibroses","enrollment":45},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT01234922","phase":"PHASE2","title":"Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-02","conditions":"Hypertension, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":6},{"nctId":"NCT00702260","phase":"NA","title":"Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-01","conditions":"Hypertension","enrollment":39},{"nctId":"NCT00702091","phase":"NA","title":"Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-01","conditions":"Hypertension","enrollment":39},{"nctId":"NCT00281593","phase":"PHASE3","title":"Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1354},{"nctId":"NCT01867047","phase":"NA","title":"ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-06","conditions":"Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension","enrollment":59},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00608465","phase":"PHASE4","title":"Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2006-05","conditions":"Metabolic Syndrome X","enrollment":4},{"nctId":"NCT01856361","phase":"NA","title":"Ramipril for the Treatment of Oligospermia","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-07","conditions":"Oligospermia, Teratospermia, Asthenozoospermia","enrollment":2},{"nctId":"NCT00367939","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":132},{"nctId":"NCT00219063","phase":"PHASE3","title":"A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":"Hypertension","enrollment":844},{"nctId":"NCT00219089","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Hypertension, Diabetes Mellitus","enrollment":839},{"nctId":"NCT02791958","phase":"PHASE2","title":"Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy","status":"UNKNOWN","sponsor":"Ferrer Internacional S.A.","startDate":"2016-03","conditions":"Hypertension","enrollment":528},{"nctId":"NCT01504828","phase":"NA","title":"Cardiac Energetics and Function in Normal Human Ageing","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2012-07","conditions":"Left Ventricular Function Systolic Dysfunction, Left Ventricular Function Diastolic Dysfunction, Ageing","enrollment":135},{"nctId":"NCT00946621","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-10","conditions":"Hypertension","enrollment":48},{"nctId":"NCT00946465","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-10","conditions":"Hypertension","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RAMIPRIL HOE498","genericName":"RAMIPRIL HOE498","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ramipril is a small molecule inhibitor of the angiotensin-converting enzyme, used to treat conditions such as hypertension and acute heart failure. It is available in a 10 mg capsule form and has been studied in combination with other interventions, including goal-directed preload and afterload decrement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}